Figure 4.

A GLA-SE adjuvanted vaccine elicits common TCRβ clonotype usage. (A and B) Circos plots of shared TCRβ CDR3 amino acid sequences in CD38⁺ICOS⁺CXCR5⁺PD-1⁺ cTfh cells from donors who received the P27A vaccine in (A) Alum or (B) GLA-SE. Alum group, n = 7; GLA-SE group, n = 8. Each line represents a TCRβ CDR3 amino acid sequence shared with another sample, and a different color was used for each participant. (C) Quantification of the number of shared CD38⁺ICOS⁺CXCR5⁺PD-1⁺ cTfh TCRβ CDR3 amino acid sequences per donor either before vaccination (P = 0.5536; left, sharing between day 0 samples) or 7 d after the third vaccination (P = 0.0089; right, sharing between day 63 samples). Alum group, n = 7; GLA-SE group, n = 8. (D) TCRβ gene usage and CDR3 amino acid sequence of the TCRβ CDR3 clonotypes shared between GLA-SE–vaccinated individuals at day 63. P values were calculated using a two-tailed unpaired Student’s t test. Each symbol represents one individual; those who received Alum are shown in black, and those who received GLA-SE are in white. Data are from one clinical trial.